PolyMedix is a biotechnology company that is developing novel, synthetic small molecule compounds that mimic the activity of large natural proteins - compounds called biomimetics. We focus on creating new therapeutic drugs to meet major unmet medical needs for treatment of serious, life threatening, acute disorders. Our initial programs involve new drug treatments for infectious diseases, and acute cardiovascular bleeding disorders. Using our proprietary computational drug design technology, we have created novel antibiotic and heptagonist drug compounds, and plan to file Investigational New Drug (IND) applications with the U.S. Food and Drug Administration (FDA) for each of these product candidates during the first quarter of 2008.

Our product candidates have been rationally selected because we believe they represent attractive medical and commercial opportunities and are characterized by:

• Major unmet medical needs;
• Relatively short clinical trials to demonstrate proof of principle of clinical utility;
• Indications that may allow for accelerated regulatory review or development paths;
• Objective clinical endpoints and assessment criteria; and
• Availability of animal models that are often considered predictive of potential human activity.

return to top ^